A Study of DS5361b in Participants With Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.

Key facts

Study ID

NCT07182591

Run by

Daiichi Sankyo

People needed

192

Starts

2025-10-02

Expected to finish

2030-12-03

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Sarasota, Florida, United States (enrolling)
• Research Site — Providence, Rhode Island, United States (enrolling)
• Research Site — Irving, Texas, United States (enrolling)
• Research Site — San Antonio, Texas, United States (enrolling)
• Research Site — Fairfax, Virginia, United States (enrolling)
• Research Site — Kashiwa, Japan (enrolling)
• Research Site — Kōtoku, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.